. 2016 Aug 19;5(8):e003558. doi: 10.1161/JAHA.116.003558

Table 4.

ASCVD Events Prevented in 10 Years by Statin‐Eligible Group and When the Percentages of Statin‐Eligible Adults on Statins Vary

Variable Statin‐Eligible Group	Sample, n	Population, N	Statin Intensity	∅Statin ASCVD₁₀, %	∅Statin ASCVD₁₀, n	⊕Statin ASCVD₁₀, n	Change ASCVD₁₀ Events, n	ASCVD₁₀ RRR, %	ASCVD₁₀ ARR, %	NNT
ASCVD	242	5 734 435	High	36.6	2 098 412	1 472 264	626 148	30.2	10.9	9
LDL ≥190	142	5 016 479	High	9.5	478 091	207 871	270 220	63.6	5.4	19
⊕DM ASCVD₁₀ ≥7.5%	273	5 435 130	Moderate‐high^a	20.3	1 102 617	751 566	351 051	35.0	6.5	15
⊕DM ASCVD₁₀ <7.5%	99	3 229 536	Moderate	4.3	138 162	94 013	44 148	32.2	1.4	73
∅DM ASCVD₁₀ ≥7.5%	589	16 022 464	Moderate‐High^b	13.5	2 161 319	1 228 995	932 324	44.8	5.8	17
∅DM ASCVD₁₀ 5–7.4%	277	9 405 669	Moderate	6.3	590 423	378 424	211 999	35.9	2.3	44
100% statin‐eligible treated	1622	44 843 712		14.6	6 569 024	4 133 133	2 435 890	41.1	5.4	18
Only ASCVD₁₀ ≥7.5%^c	1246	32 208 508		18.1	5 840 439	3 660 696	2 179 743	43.5	6.8	15
Only ASCVD₁₀ <7.5%^d	376	12 635 205		5.8	728 585	472 437	256 147	35.0	2.0	49
75% statin‐eligible treated	1216	33 632 784		14.6	4 926 768	3 099 850	1 826 918	41.1	5.4	18
Only ASCVD₁₀ ≥7.5%^c	934	24 156 381		18.1	4 380 329	2 745 522	1 634 807	43.5	6.8	15
Only ASCVD₁₀ <7.5%^d	282	9 476 403		5.8	546 439	354 328	192 110	35.0	2.0	49
50% statin‐eligible treated	811	22 421 856		14.7	3 284 512	2 066 567	1 217 945	41.1	5.4	18
Only ASCVD₁₀ ≥7.5%^c	623	16 104 254		18.1	2 920 220	1 830 348	1 089 872	43.5	6.8	15
Only ASCVD10 <7.5%^d	188	6 317 602		5.8	364 292	236 218	128 074	35.0	2.0	49

ASCVD indicates atherosclerotic cardiovascular disease. ⊕ Statin ASCVD₁₀, n indicates number of ASCVD events over 10 years with statins; ⊕DM, DM present; ∅DM, DM absent; ∅Statin ASCVD₁₀, %, 10‐year ASCVD risk without a statin; ∅Statin ASCVD₁₀, n, number of ASCVD events over 10 years without a statin; ARR, absolute risk reduction; DM, diabetes mellitus; NNT, 10‐year number needed‐to‐treat to prevent an ASCVD event; RRR, relative risk reduction.

Fifty percent of patients with (⊕) diabetes mellitus (DM) and ASCVD₁₀ ≥7.5% receive high‐intensity and 50% receive moderate‐intensity statins.

Seventy‐five percent of patients without (∅) diabetes mellitus receive high‐intensity and 25% receive moderate‐intensity statins.

Includes ASCVD, LDL ≥190, and patients with and without diabetes mellitus and 10‐year ASCVD risk (ASCVD₁₀) ≥7.5% and excludes lower‐risk participants with (⊕) diabetes mellitus (DM) and ASCVD₁₀ <7.5% and without (∅) diabetes mellitus (DM) and ASCVD₁₀ 5–7.4%.

Includes only lower risk participants with diabetes mellitus and ASCVD₁₀ <7.5% and without diabetes and ASCVD₁₀ 5–7.4%.